Comparison of Clinicopathological Characteristics of BRCA1 and BRCA2 Carriers with Breast Cancer: The Role of Ki-67 Index
Received Date : 30 Jan 2021
Accepted Date : 23 Sep 2021
Available Online : 06 Oct 2021
Doi: 10.37047/jos.2021-81821 - Article's Language: EN
J Oncol Sci. 2021;7(3):91-7
This is an open access article under the CC BY-NC-ND license
Objective: To elucidate the clinicopathological differences between breast cancer 1 (BRCA1) and BRCA2 carriers among patients with breast carcinoma. Material and Methods: The present retrospective study explored the demographic and clinicopathological features of 57 BRCA carriers with breast cancer. The age, family history, tumor Ki-67 index, tumor grade, hormone receptor status (estrogen and progesterone), human epidermal growth factor receptor 2 status, tumor T and N Stage, tumor multifocality, and tumor treatment modalities (surgical or adjuvant/neoadjuvant chemotherapy) were recorded for each patient from the hospital automation system. Results: The patients with a median age of 39 (range: 23-68 years) years comprised 35% BRCA1 and 65% BRCA2 carriers. Higher median Ki-67 index was revealed for the BRCA1 group than for the BRCA2 group (40% vs. 80%, p=0.006). The proportions of patients with estrogen receptor (+) and progesterone receptor (+) tumors were 35.0% and 35.0%, respectively, in the BRCA1 group, whereas 75.7% and 73.0%, respectively, in the BRCA2 group (p value 0.003 and 0.005, respectively). The BRCA1 group demonstrated significantly higher proportion of triple-negative patient rate as compared to the BRCA2 group (21.6% vs. 55.0%, p=0.011). Multivariate logistic regression analysis conducted with the Ki-67 index, estrogen receptor status, progesterone receptor status, and triple-negative disease status identified the Ki-67 index as the only independent predictive factor that could distinguish the BRCA1 from the BRCA2 mutation. A high Ki-67 index (>45%) was correlated with the BRCA1 mutation (odds ratio: 0.970, 95% confidence interval: 0.943-0.999, p=0.044). Conclusion: A high Ki-67 index is more frequently prevalent in BRCA1 carriers than in BRCA2 mutation carriers among patients with breast cancer.
  1. Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol. 2016;59(4):651-672. [Crossref]  [PubMed] 
  2. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017;165(1):193-200. [Crossref]  [PubMed]  [PMC] 
  3. Demir S, Tozkir H, Gurkan H, et al. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey. J BUON. 2020;25(3):1337-1347. [PubMed] 
  4. Lee A, Moon BI, Kim TH. BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med. 2020;40(2):114-121. [Crossref]  [PubMed]  [PMC] 
  5. Duzkale N, Eyerci N. Double heterozygosity in the BRCA1/2 genes in a Turkish patient with bilateral breast cancer: a case report. Oncologie. 2020;22(3):161-166. [Crossref] 
  6. Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004;10(6):2029-2034. [Crossref]  [PubMed] 
  7. Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018; 19(2):169-180. [Crossref]  [PubMed]  [PMC] 
  8. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-410. [Crossref]  [PubMed] 
  9. Loi M, Desideri I, Olmetto E, et al. BRCA mutation in breast cancer patients: Prognostic impact and implications on clinical management. Breast J. 2018;24(6):1019-1023. [Crossref]  [PubMed] 
  10. McCrorie AD, Ashfield S, Begley A, et al. Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers. J Pathol Clin Res. 2020;6(2):146-153. [Crossref]  [PubMed]  [PMC] 
  11. Hashmi AA, Hashmi KA, Irfan M, et al. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes. 2019;12(1):605. [Crossref]  [PubMed]  [PMC] 
  12. Chen X, He C, Han D, et al. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Future Oncol. 2017;13(9):843-857. [Crossref]  [PubMed] 
  13. Focke CM, Bürger H, van Diest PJ, et al; German Breast Screening Pathology Initiative. Interlaboratory variability of Ki67 staining in breast cancer. Eur J Cancer. October 2017; 84:219-227. [PubMed] 
  14. Sønderstrup IMH, Jensen MR, Ejlertsen B, et al. Subtypes in BRCA-mutated breast cancer. Hum Pathol. February 2019;84:192-201. [Crossref]  [PubMed] 
  15. Parkes EE, Walker SM, Taggart LE, et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst. 2016; 109(1):djw199. [Crossref]  [PubMed]  [PMC] 
  16. Aydin F, Akagun T, Yildiz B, Fidan E, Ozdemir F, Kavgaci H. Clinicopathologic characteristics and BRCA-1/BRCA-2 mutations of Turkish patients with breast cancer. Bratisl Lek Listy. 2011;112(9):521-523. [PubMed] 
  17. Bisgin A, Boga I, Yalav O, Sonmezler O, Tug Bozdogan S. BRCA mutation characteristics in a series of index cases of breast cancer selected independent of family history. Breast J. 2019;25(5):1029-1033. [Crossref]  [PubMed] 
  18. Atcı MM, Geredeli Ç, Ay S, et al. Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles: a retrospective study. Eur J Breast Health. 2021;17(2):123-127. [Crossref]  [PubMed]  [PMC]